Gabi Tarcic - 04 Jun 2026 Form 4 Insider Report for Evogene Ltd. (EVGN)

Reporting relationship: Chief Development Officer
Issuer ticker: EVGN
Reported as of: 04 Jun 2026
Net transaction value: +$677
SEC form: 4
Accepted by SEC: 26 Aug 2026, 16:00:55 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Nitsan Deutsch, attorney-in-fact

Key filing fact

Gabi Tarcic filed Form 4 for Evogene Ltd. (EVGN) on 26 Aug 2026.

Key facts

This page summarizes Gabi Tarcic's Form 4 filing for Evogene Ltd. (EVGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Aug 2026, 16:00.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: +$677.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002085020 Primary reporting owner

Tarcic Gabi

Relationship: Chief Development Officer
Address: 6 HASHIKMA ST., MEVASERET ZION, ISRAEL
Signature: /s/ Nitsan Deutsch, attorney-in-fact
Signature date: 25 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVGN transaction

Ordinary Shares

Purchase

Transaction value: $677
Shares: +1,129
Change %
Price: $0.6000
Shares after: 1,129
Date: 04 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVGN holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 40,000
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 40,000
Exercise price: $2.30
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options reported in this row vest over a period of four years, with 25% vesting upon the first anniversary of the November 20, 2024 grant date, and the remainder vesting on an equal quarterly basis (6.25% per quarter) over the following twelve quarters, such that all options will be fully vested on the four-year anniversary of the November 20, 2024 grant date.

Footnote F2

There were no transactions in the securities reported in this row, and the Reporting Person's holdings in these securities is being provided for informational purposes only.

SEC remarks

Exhibit 24.1 - Power of Attorney.